1. DIPG-53. Long-term survival from a Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radioimmunotherapeutic124I-omburtamab for treatment of diffuse intrinsic pontine glioma (DIPG). (3rd June 2022) Authors: Souweidane, Mark M; Kramer, Kim; Pandit-Tasker, Neeta; Haque, Sofia; Zanzonico, Pat; Carrasquillo, Jorge; Lyashchenko, Serge K; Thakur, Sunitha B; Khakoo, Yasmin; Dunkel, Ira J; Donzelli, Maria; Lewis, Jason S; Cheung, Nai-Kong V; Larson, Steve M; Reiner, Anne S; Panageas, Katherine S; Manino, Ni... Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 1 Page Start: i30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗